Click to read Digital healthcare, a globally booming market, has been catalyzed by the events of COVID-19. In Asia Pacific, in particular, a rapidly expanding population, an empowered and tech-savvy middle class and physician shortage has created the perfect conditions for digital health innovation. A new era of digital healthcare…

On 5 October 2020, the Parliament approved the job creation law (RUU Cipta Kerja, commonly known as the “Omnibus Law”). The Omnibus Law amends a number of existing laws. On 5 October 2020, the Parliament approved the job creation law (RUU Cipta Kerja, commonly known as the “Omnibus Law“). The…

In brief On 5 October 2020, the Parliament approved the job creation law (RUU Cipta Kerja, commonly known as the “Omnibus Law”). The Omnibus Law amends a number of existing laws, including the following: Law No. 7 of 2014 on Trade (“Trade Law”) Law No. 39 of 2009 on Special…

In brief On 5 October, The Parliament approved the job creation law (RUU Cipta Kerja, commonly known as the “Omnibus Law”). The Omnibus Law is expected to take effect within 30 days, upon signing by the President. Initially, the Government proposed two separate omnibus laws, with the first focusing on…

On 5 October, the Parliament approved the job creation law (RUU Cipta Kerja) – commonly known as the “Omnibus Law”. The Omnibus Law amends a number of existing laws, including Law No. 25 of 2007 on Capital Investment (“Investment Law”). This alert will focus on the impacts of the Omnibus Law on the Investment Law.

One of the preliminary methods to check if a person has been infected with COVID-19 is a rapid antibody test. In addition, under COVID-19 Task Force Circular Letter No. 7 of 2020 currently, a rapid antibody or PCR (Polymerase Chain Reaction) test result is a requirement for anyone taking public transportation for domestic (interprovincial or intercity) and international travel in Indonesia. Although the accuracy of rapid antibody tests is questionable, the rapid antibody test is the easiest and quickest way to identify COVID-19 exposure.

Because it is easy to use, there has been high demand for rapid antibody tests. To ensure a reasonable price, on 6 July, the Directorate General of Healthcare Services (“DGHS”) (i.e., a division under the Ministry of Health (“MOH”) issued Circular Letter No. HK.02.02/I/2875/2020 on the maximum tariff of Rapid Antibody Tests (“DGHS Circular Letter 02”).

DGHS Circular Letter 02 is an implementing rule of MOH Decision No. HK.01.07/MENKES/247/2020 on Guidelines on Prevention and Control of Corona Virus Diseases (COVID-19).

As the COVID-19 pandemic continues to have a profound impact on businesses, companies have started to focus on navigating the medium- to long-term implications of this crisis. While disruption may pose challenges, we have also seen how various sectors are embracing and accelerating digital transformation as a way to achieve…

The government has issued a draft of a new omnibus law, which addresses various issues, as we have discussed in our previous client alert here. This client alert covers specific proposed key changes and implications in healthcare/life science and trade sectors set out in the draft of the job creation…

In September 2019, several news outlets reported that the government of the Republic of Indonesia was preparing a new law that would regulate several provisions in various industry sectors in one law, with a view to strengthening the Indonesian economy, increasing competitiveness and creating jobs. This is the first time…

Background The Minister of Health (“MOH”) has issued a new regulation on the classification and licensing of hospitals. The new regulation relaxes some provisions that were deemed not favorable for business actors. Contents and Implications MOH Regulation No. 30 of 2019 on the Classification and Licensing of Hospitals (“MOH Regulation…